These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30153704)

  • 1. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
    Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
    Jimeno A; Sharma MR; Szyldergemajn S; Gore L; Geary D; Diamond JR; Fernandez Teruel C; Soto Matos-Pita A; Iglesias JL; Cullell-Young M; Ratain MJ
    Invest New Drugs; 2017 Aug; 35(4):471-477. PubMed ID: 28105566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
    Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
    Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
    Elez ME; Tabernero J; Geary D; Macarulla T; Kang SP; Kahatt C; Pita AS; Teruel CF; Siguero M; Cullell-Young M; Szyldergemajn S; Ratain MJ
    Clin Cancer Res; 2014 Apr; 20(8):2205-14. PubMed ID: 24563480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
    Paz-Ares L; Forster M; Boni V; Szyldergemajn S; Corral J; Turnbull S; Cubillo A; Teruel CF; Calderero IL; Siguero M; Bohan P; Calvo E
    Invest New Drugs; 2017 Apr; 35(2):198-206. PubMed ID: 27873130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
    J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
    Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
    Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
    Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
    Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
    Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.
    Cote GM; Haddox CL; Choy E; Merriam PA; Mazzola E; Venkataraman V; Alcindor T; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2024 Jul; 30(13):2702-2708. PubMed ID: 38723278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
    Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
    Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
    Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
    Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
    Vey N; Prebet T; Thalamas C; Charbonnier A; Rey J; Kloos I; Liu E; Luan Y; Vezan R; Graef T; Recher C
    Leuk Lymphoma; 2017 Aug; 58(8):1880-1886. PubMed ID: 27911138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
    Fernández-Teruel C; Lubomirov R; Fudio S
    J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.